Neumora Therapeutics (NMRA) News Today

Neumora Therapeutics (NASDAQ:NMRA) Trading 7.5% Higher - Here's Why

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - HC Wainwright issued their Q3 2024 earnings estimates for shares of Neumora Therapeutics in a note issued to investors on Tuesday, October 1st. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.33) per share for the qua

Logos Global Management LP cut its holdings in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 21.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 300,000 shares of the company's stock after selli

HC Wainwright assumed coverage on shares of Neumora Therapeutics in a report on Tuesday. They set a "buy" rating and a $30.00 price objective on the stock.

Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3.1%

Logos Global Management LP reduced its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 21.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 300,000 shares of the company's stock after

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation o

Rhumbline Advisers raised its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 488.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,258 shares of the company's

Callan Capital LLC increased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 222.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 661,194 shares of the company's stock after acquiring

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Robert A. Lenz sold 30,788 shares of the business's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the transaction, the insider now directly owns 339,205 shares of the company's stock, valued at $4,006,011.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 5.2%

Bank of New York Mellon Corp grew its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 474.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 235,593 shares of the company's stock after purchasing an add

Needham & Company LLC reissued a "buy" rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research note on Thursday.

Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 7.2%

Royal Bank of Canada reissued an "outperform" rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a report on Wednesday.

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a b

Neumora Therapeutics (NASDAQ:NMRA) Shares Up 2.6%

Neumora Therapeutics (NASDAQ:NMRA) Trading Down 5.7%

SG Americas Securities LLC bought a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 57,607 shares of the company's stock, valued at approximately $566,00

Vanguard Group Inc. reduced its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 12.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 334,330 shares of the company's stock after selling 46,624 shares during the period. Vanguard Group Inc. o

Neumora Therapeutics (NASDAQ:NMRA) Stock Price Down 3.6%

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37).

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Research analysts at William Blair issued their FY2028 earnings per share estimates for Neumora Therapeutics in a report issued on Tuesday, August 6th. William Blair analyst M. Minter anticipates that the company will post earnings per shar

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have issued

Price T Rowe Associates Inc. MD acquired a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 752,924 shares of the company's stock, valued at app

Neumora Therapeutics (NASDAQ:NMRA) Sees Unusually-High Trading Volume

Kennedy Capital Management LLC acquired a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 136,828 shares of the company's stock, valued

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 8,860,000 shares, a growth of 21.4% from the June 30th total of 7,300,000 shares. Based on an average trading volume of 788,400 shares, the short-interest ratio is currently 11.2 days. Currently, 16.2% of the company's stock are sold short.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have

Mizuho initiated coverage on Neumora Therapeutics in a report on Monday. They set an "outperform" rating and a $20.00 price target for the company.